# US 2024/0391875 A1 · Isoquinolinones and quinolinones as modulators of polrmt

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0391875 A1
- Document ID: US20240391875A1
- Status: Published application
- Kind: A1
- Application number: 18/687,692
- Filed: 2022-08-30
- Published: 2024-11-28
- Earliest claimed: 2021-08-30
- Assignees: Pretzel Therapeutics, Inc.
- Applicants: Pretzel Therapeutics, Inc.
- Inventors: Gabriel Martinez Botella; Jeremy Green; Paul S. Charifson; Simon Giroux; Andrew Griffin
- Web page: https://patentgrep.com/patent/US20240391875A1

## CPC

- A61K 31/4704: 2-Quinolinones, e.g. carbostyril
- C07D 217/26: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/497: containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/5386: spiro-condensed or forming part of bridged ring systems
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- C07B 59/004: {Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium}
- C07D 217/24: Oxygen atoms
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 487/08: Bridged systems
- C07D 498/08: Bridged systems
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07B 2200/07: Optical isomers
- C07B 2200/09: Geometrical isomers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention provides novel isoquinolinone and quinolinone compounds that are inhibitors of mitochondrial RNA polymerase for treating various diseases such as cancer and others associated with metabolic disorders and mitochondrial dysfunction.

## Claims

### Claim 1

A compound of formula (I), or a pharmaceutically acceptable salt thereof:
wherein:
Z is O, C(H)(R1), C6H4, C(O), C(O)N(R7), or N(R2);
W is C3-C8 cycloalkyl, C4-C12 bicyclic, C4-C10 cycloalkenyl, C6-C12 aryl, or 5- to 12-membered heteroaryl, any of which is substituted with one or more groups, each independently selected from the group consisting of fluoro, chloro, trifluoromethyl, difluoromethyl, cyano, hydroxyl, C1-C4 alkoxyl, and C1-C4 alkyl optionally substituted with one or more deuterium or hydroxyl;
R is hydrogen, or C1-C6 alkyl optionally substituted with one or more groups each independently selected from the group consisting of fluoro, hydroxyl, C1-C4 alkoxyl, cyano, C1-C4 haloalkoxyl, carboxyl, C(O)NR5R6, NR5R6 and NR2R3,
or R is C6-C12 aryl optionally substituted with one or more groups, each independently selected from the group consisting of fluoro, chloro, C1-C4 alkyl, trifluoromethyl, difluoromethyl, cyano, hydroxyl, NR5R6, and C1-C4 alkoxyl,
or R is hydroxyl, NR1R2, C(O)R3, C1-C4 haloalkoxyl, CH2CH2R8, CR3R4C(O)OR5, or 4-7 membered cyclic ring containing one or more heteroatoms, such cyclic ring is optionally substituted with C(O)R1, NR1—C(O)—R1, or CR3R4C(O)NR5R6;
each R1 is independently hydrogen, C1-C4 alkoxyl, or C1-C4 alkyl optionally substituted with one or more fluoro groups;
each R2 is independently hydrogen, C1-C4 alkyl optionally substituted with one or more fluoro groups, C(O)C1-C4 alkyl optionally substituted with one or more fluoro or methoxyl groups, C(O)-cycloheteroalkyl optionally substituted with methyl or acetate, or C(O)NHC1-C4 alkyl optionally substituted with one or more fluoro groups;
R3 and R4 are each independently hydrogen or C1-C4 alkyl optionally substituted with one or more groups each independently selected from the group consisting of fluoro, hydroxyl, C1-C4 alkoxyl, C1-C4 haloalkoxyl, and NR5R6;
R5 and R6 are each independently hydrogen, cycloheteroalkyl optionally substituted with acetate, or C1-C4 alkyl optionally substituted with one or more groups each independently selected from the group consisting of fluoro, hydroxyl, cyano, C1-C4 alkoxyl, C1-C4 haloalkoxyl, and NR1R2,
or if R5 and R6 are attached to the same nitrogen atom, R5 and R6 together with their connecting nitrogen form a 3- to 7-membered heterocyclic ring or 6- to 12-membered heterobicyclic ring, each such heterocyclic ring or heterobicyclic ring optionally containing another heteroatom that is N, O, S, S(O), SO2R1, or S(O)(NR1) and each such heterocyclic ring or heterobicyclic ring is optionally substituted with one or more groups each independently selected from the group consisting of fluoro, chloro, and C1-C4 alkyl optionally substituted with one or more fluoro, C1-alkoxyl or hydroxyl, and each such heterocyclic ring or heterobicyclic ring is further optionally substituted with cycloalkyl, cyano, carboxyl, C(O)R1, C(O)NR1R2, imine, oxo, NR1—C(O)—R1, SO2R1, or C1-C4 alkylcarboxylate;
R7 is H or C1-C6 alkyl; and
R8 is aryl optionally substituted with one or more groups, each independently selected from the group consisting of fluoro, chloro, C1-C4 alkyl, trifluoromethyl, difluoromethyl, cyano, hydroxyl, and C1-C4 alkoxyl,
or R8 is OR1, NR1R2, C(O)R1, or C(O)NR2R2.

### Claim 2 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
Z is O, C(H)(R1), C6H4, C(O), C(O)N(R7), or N(R2);
W is C6 cycloalkyl, C5 bicyclic, C6 cycloalkenyl, C6 aryl or 5-membered heteroaryl, any of which is substituted with one or more groups, each independently selected from the group consisting of fluoro, chloro, cyano, and C1-C2 alkyl optionally substituted with one or more deuterium or hydroxyl;
R is hydrogen, or C1-C4 alkyl optionally substituted with one or more groups each independently selected from the group consisting of fluoro, hydroxyl, C1 alkoxyl, cyano, carboxyl, C(O)NR5R6, and NR2R3,
or R is hydroxyl, NR1R2, C(O)R3, CR3R4C(O)OR5, or 4-7 membered cyclic ring containing one or more heteroatoms, such cyclic ring is optionally substituted with C(O)R1, NR1—C(O)—R1, or CR3R4C(O)NR5R6;
each R1 is independently hydrogen, C1 alkoxyl, or C1-C2 alkyl;
each R2 is independently hydrogen, C1-C2 alkyl optionally substituted with one or more fluoro groups, C(O)C1-C4 alkyl optionally substituted with methoxy, or C(O)-cycloheteroalkyl optionally substituted with methyl or acetate;
R3 and R4 are each independently hydrogen or C1 alkyl optionally substituted with C1 alkoxyl;
R5 and R6 are each independently hydrogen, C1-C2 alkyl, or cycloheteroalkyl substituted with acetate;
or if R5 and R6 are attached to the same nitrogen atom, R5 and R6 together with their connecting nitrogen form a 5- or 6-membered heterocyclic ring or 8-membered heterobicyclic ring, each such heterocyclic ring or heterobicyclic ring optionally containing another heteroatom that is N, O, S, S(O), SO2R1, or S(O)(NR1) and each such heterocyclic ring or heterobicyclic ring is optionally substituted with one or more groups each independently selected from the group consisting of fluoro and C1-C2 alkyl optionally substituted with one or more fluoro, C1-alkoxyl or hydroxyl, and each such heterocyclic ring or heterobicyclic ring is further optionally substituted with cyano, carboxyl, C(O)R1, C(O)NR1R2, NR1—C(O)—R1, or SO2R1; and
R7 is C1 alkyl.

### Claim 3 (depends on 2)

The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein:
Z is O or C6H4;
W is C6 aryl substituted with one or more groups, each independently selected from the group consisting of fluoro, chloro, and C1-C2 alkyl;
R is hydrogen, C1-C4 alkyl optionally substituted with one or more groups each independently selected from the group consisting of fluoro, C1 alkoxyl, cyano, carboxyl, and C(O)NR5R6;
each R1 is independently hydrogen or C1-C2 alkyl;
each R2 is independently hydrogen;
R5 and R6 are each independently hydrogen;
or if R5 and R6 are attached to the same nitrogen atom, R5 and R6 together with their connecting nitrogen form a 5- or 6-membered heterocyclic ring or 8-membered heterobicyclic ring, each such heterocyclic ring or heterobicyclic ring optionally containing another heteroatom that is N or O, and each such heterocyclic ring or heterobicyclic ring is optionally substituted with one or more groups each independently selected from the group consisting of fluoro and C1-C2 alkyl optionally substituted with one or more fluoro, or hydroxyl, and each such heterocyclic ring or heterobicyclic ring is further optionally substituted with cyano, carboxyl, C(O)R1, C(O)NR1R2, or SO2R1.

### Claim 4 (depends on 3)

The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein:
Z is O;
W is C6 aryl substituted with one or more groups, each independently selected from the group consisting of fluoro, chloro, and C1 alkyl;
R is C2 alkyl substituted with C(O)NR5R6; and
R5 and R6 are attached to the same nitrogen atom, and together with their connecting nitrogen form a 6-membered heterocyclic ring substituted with carboxyl.

### Claim 5 (depends on 3)

The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein:
Z is O;
W is C6 aryl substituted with one or more groups, each independently selected from the group consisting of fluoro and C1 alkyl; and
R is C1 alkyl substituted with cyano.

### Claim 6 (depends on 3)

The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein:
Z is O;
W is C6 aryl substituted with two C1 alkyl; and
R is C1 alkyl substituted with cyano.

### Claim 7 (depends on 2)

A pharmaceutical composition comprising the compound of claim 2, and a pharmaceutically acceptable excipient.

### Claim 8 (depends on 3)

A pharmaceutical composition comprising the compound of claim 3, and a pharmaceutically acceptable excipient.

### Claim 9

A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

### Claim 10 (depends on 9)

The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

### Claim 11 (depends on 10)

The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

### Claim 12 (depends on 10)

The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

### Claim 13 (depends on 10)

The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

### Claim 14 (depends on 10)

The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein the compound is:

### Claim 15 (depends on 10)

A pharmaceutical composition comprising the compound of claim 10, and a pharmaceutically acceptable excipient.

### Claim 16

A method of inhibiting the activity of POLRMT with a compound of formula (I), or a pharmaceutically acceptable salt thereof:
wherein:
Z is O, C(H)(R1), C6H4, C(O), C(O)N(R7), or N(R2);
W is C3-C8 cycloalkyl, C4-C12 bicyclic, C4-C10 cycloalkenyl, C6-C12 aryl, or 5- to 12-membered heteroaryl, any of which is substituted with one or more groups, each independently selected from the group consisting of fluoro, chloro, trifluoromethyl, difluoromethyl, cyano, hydroxyl, C1-C4 alkoxyl, and C1-C4 alkyl optionally substituted with one or more deuterium or hydroxyl;
R is hydrogen, or C1-C6 alkyl optionally substituted with one or more groups each independently selected from the group consisting of fluoro, hydroxyl, C1-C4 alkoxyl, cyano, C1-C4 haloalkoxyl, carboxyl, C(O)NR5R6, NR5R6 and NR2R3,
or R is C6-C12 aryl optionally substituted with one or more groups, each independently selected from the group consisting of fluoro, chloro, C1-C4 alkyl, trifluoromethyl, difluoromethyl, cyano, hydroxyl, NR5R6, and C1-C4 alkoxyl,
or R is hydroxyl, NR1R2, C(O)R3, C1-C4 haloalkoxyl, CH2CH2R8, CR3R4C(O)OR5, or 4-7 membered cyclic ring containing one or more heteroatoms, such cyclic ring is optionally substituted with C(O)R1, NR1—C(O)—R1, or CR3R4C(O)NR5R6;
each R1 is independently hydrogen, C1-C4 alkoxyl, or C1-C4 alkyl optionally substituted with one or more fluoro groups;
each R2 is independently hydrogen, C1-C4 alkyl optionally substituted with one or more fluoro groups, C(O)C1-C4 alkyl optionally substituted with one or more fluoro or methoxyl groups, C(O)-cycloheteroalkyl optionally substituted with methyl or acetate, or C(O)NHC1-C4 alkyl optionally substituted with one or more fluoro groups;
R3 and R4 are each independently hydrogen or C1-C4 alkyl optionally substituted with one or more groups each independently selected from the group consisting of fluoro, hydroxyl, C1-C4 alkoxyl, C1-C4 haloalkoxyl, and NR5R6;
R5 and R6 are each independently hydrogen or C1-C4 alkyl optionally substituted with one or more groups each independently selected from the group consisting of fluoro, hydroxyl, cyano, C1-C4 alkoxyl, C1-C4 haloalkoxyl, and NR1R2;
or if R5 and R6 are attached to the same nitrogen atom, R5 and R6 together with their connecting nitrogen form a 3- to 7-membered heterocyclic ring or 6- to 12-membered heterobicyclic ring, each such heterocyclic ring or heterobicyclic ring optionally containing another heteroatom that is N, O, S, S(O), SO2R1, or S(O)(NR1) and each such heterocyclic ring or heterobicyclic ring is optionally substituted with one or more groups each independently selected from the group consisting of fluoro, chloro, and C1-C4 alkyl optionally substituted with one or more fluoro, C1-alkoxyl or hydroxyl, and each such heterocyclic ring or heterobicyclic ring is further optionally substituted with cycloalkyl, cyano, carboxyl, C(O)R1, C(O)NR1R2, imine, oxo, NR1—C(O)—R1, SO2R1, or C1-C4 alkylcarboxylate; and
R7 is H or C1-C6 alkyl; and
R8 is aryl optionally substituted with one or more groups, each independently selected from the group consisting of fluoro, chloro, C1-C4 alkyl, trifluoromethyl, difluoromethyl, cyano, hydroxyl, and C1-C4 alkoxyl, or R8 is OR1, NR1R2, C(O)R1, or C(O)NR2R2.

### Claim 17 (depends on 16)

The method of claim 16, wherein:
Z is O, C(H)(R1), C6H4, C(O), C(O)N(R7), or N(R2);
W is C6 cycloalkyl, C5 bicyclic, C6 cycloalkenyl, C6 aryl or 5-membered heteroaryl, any of which is substituted with one or more groups, each independently selected from the group consisting of fluoro, chloro, cyano, and C1-C2 alkyl optionally substituted with one or more deuterium or hydroxyl;
R is hydrogen, or C1-C4 alkyl optionally substituted with one or more groups each independently selected from the group consisting of fluoro, hydroxyl, C1 alkoxyl, cyano, carboxyl, C(O)NR5R6, and NR2R3,
or R is hydroxyl, NR1R2, C(O)R3, CR3R4C(O)OR5, or 4-7 membered cyclic ring containing one or more heteroatoms, such cyclic ring is optionally substituted with C(O)R1, NR1—C(O)—R1, or CR3R4C(O)NR5R6;
each R1 is independently hydrogen, C1 alkoxyl, or C1-C2 alkyl;
each R2 is independently hydrogen, C1-C2 alkyl optionally substituted with one or more fluoro groups, C(O)C1-C4 alkyl optionally substituted with methoxy, or C(O)-cycloheteroalkyl optionally substituted with methyl or acetate;
R3 and R4 are each independently hydrogen or C1 alkyl optionally substituted with C1 alkoxyl;
R5 and R6 are each independently hydrogen, C1-C2 alkyl, or cycloheteroalkyl substituted with acetate;
or if R5 and R6 are attached to the same nitrogen atom, R5 and R6 together with their connecting nitrogen form a 5- or 6-membered heterocyclic ring or 8-membered heterobicyclic ring, each such heterocyclic ring or heterobicyclic ring optionally containing another heteroatom that is N, O, S, S(O), SO2R1, or S(O)(NR1) and each such heterocyclic ring or heterobicyclic ring is optionally substituted with one or more groups each independently selected from the group consisting of fluoro and C1-C2 alkyl optionally substituted with one or more fluoro, C1-alkoxyl or hydroxyl, and each such heterocyclic ring or heterobicyclic ring is further optionally substituted with cyano, carboxyl, C(O)R1, C(O)NR1R2, NR1—C(O)—R1, or SO2R1; and
R7 is C1 alkyl.

### Claim 18 (depends on 17)

The method of claim 17, wherein:
Z is O, or C6H4;
W is C6 aryl substituted with one or more groups, each independently selected from the group consisting of fluoro, chloro, and C1-C2 alkyl;
R is hydrogen, C1-C4 alkyl optionally substituted with one or more groups each independently selected from the group consisting of fluoro, C1 alkoxyl, cyano, carboxyl, and C(O)NR5R6;
each R1 is independently hydrogen or C1-C2 alkyl;
each R2 is independently hydrogen;
R5 and R6 are each independently hydrogen;
or if R5 and R6 are attached to the same nitrogen atom, R5 and R6 together with their connecting nitrogen form a 5- or 6-membered heterocyclic ring or 8-membered heterobicyclic ring, each such heterocyclic ring or heterobicyclic ring optionally containing another heteroatom that is N or O, and each such heterocyclic ring or heterobicyclic ring is optionally substituted with one or more groups each independently selected from the group consisting of fluoro and C1-C2 alkyl optionally substituted with one or more fluoro or hydroxyl, and each such heterocyclic ring or heterobicyclic ring is further optionally substituted with cyano, carboxyl, C(O)R1, C(O)NR1R2, or SO2R1.

### Claim 19 (depends on 16)

The method of claim 16, wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
